Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

PATENTS

Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD

Nature Biotechnology volume 40, pages 1319–1325 (2022)Cite this article

Subjects

Manufacturers of brand-name nebulizer solutions have employed a variety of strategies to preserve market dominance over their products but have been less successful than manufacturers of brand-name inhalers in preventing generic competition.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Brand-name market exclusivity and generic competition for nebulizer solutions.
Fig. 2: Brand-name market exclusivity and generic competition for inhalers.
Fig. 3: Brand-name market exclusivity and generic competition for nebulizer solutions with corresponding inhalers.

References

  1. Barjaktarevic, I. Z. & Milstone, A. P. Int. J. Chron. Obstruct. Pulmon. Dis. 15, 1665–1677 (2020).

    Article  CAS  Google Scholar 

  2. Turner, M. O., Patel, A., Ginsburg, S. & FitzGerald, J. M. Arch. Intern. Med. 157, 1736–1744 (1997).

    Article  CAS  Google Scholar 

  3. Cates, C. J., Welsh, E. J. & Rowe, B. H. Cochrane Database Syst. Rev. 9, CD000052 (2013).

    Google Scholar 

  4. GINA Report, Global Strategy for Asthma Management and Prevention (GINA, 2021).

  5. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2021 Report (GOLD, 2021).

  6. Medicare Part D Drug Spending by Drug (CMS, accessed 10 August 2022); https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug

  7. Feldman, W. B., Gagne, J. J. & Kesselheim, A. S. Ann. Am. Thorac. Soc. 18, 548–550 (2021).

    Article  Google Scholar 

  8. Pulmicort (GoodRx, 10 August 2022); https://www.goodrx.com/pulmicort

  9. Aerosol Delivery Devices for Respiratory Therapists: 4th Edition (AARC, 2017).

  10. Drugs@FDA: FDA-Approved Drugs (FDA, accessed 10 August 2022); https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

  11. Beall, R. F. & Kesselheim, A. S. Nat. Biotechnol. 36, 142–145 (2018).

    Article  CAS  Google Scholar 

  12. Feldman, W. B., Bloomfield, D., Beall, R. F. & Kesselheim, A. S. Health Aff. https://doi.org/10.1377/hlthaff.2021.01874 (2022).

  13. Report to Congress: The Listing of Patent Information in the Orange Book. Submitted Under Section 2(e) of the Orange Book Transparency Act of 2020 (FDA, 2020).

  14. Medicare Part B Spending by Drug (CMS, accessed 10 August 2022); https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-b-spending-by-drug

  15. The Orange Book Archives (FDA, accessed 10 August 2022); https://www.thefdalawblog.com/orange-book-archives/

  16. New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products (FDA, 2021).

  17. Frequently Asked Questions on Patents and Exclusivity (FDA, accessed 10 August 2022); https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity#What_is_the_difference_between_patents_a

  18. Medicaid State Drug Utilization (NBER, accessed 10 August 2022); https://www.nber.org/research/data/medicaid-state-drug-utilization

  19. State Drug Utilization Data 2019 (Medicaid, accessed 10 August 2022); https://data.medicaid.gov/dataset/daba7980-e219-5996-9bec-90358fd156f1

  20. State Drug Utilization Data 2020 (Medicaid, accessed 10 August 2020); https://data.medicaid.gov/dataset/cc318bfb-a9b2-55f3-a924-d47376b32ea3

  21. Marketing Status Notifications Under Section 5061 of the Federal Food, Drug, and Cosmetic Act; Content and Format: Guidance for Industry (FDA, 2020).

  22. Israel, E. et al. N. Engl. J. Med 386, 1505–1518 (2022).

    Article  CAS  Google Scholar 

  23. Apter, A. et al. J. Allergy Clin. Immunol. Pract. 10, 517–524 (2022).

    Article  Google Scholar 

  24. Teva announces its launch of the first generic PERFOROMIST®, formoterol fumarate inhalation solution, 20 mcg/2 ML, used to treat chronic obstructive pulmonary disease (COPD), in the United States. Teva (June 2021).

  25. Sinha, M. Minn. J. Law Sci. Technol. 23, 293–361 (2022).

    Google Scholar 

  26. Feldman, R. Drugs, Money, and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices (Cambridge Univ. Press, 2019).

  27. Tu, S. S. & Lemley, M. A. Wash Univ. Law Rev. 99, 1673 (2022).

Download references

Acknowledgements

This work was funded by the Commonwealth Fund, as well as from a grant (National Institutes of Health 5T32HL007633-36) to W.B.F. A.S.K.’s work was also supported by Arnold Ventures. R.B.’s work is funded by an O’Brien Institute of Public Health catalyst grant for equitable pharmaceutical innovation and access to medicines. The funders had no role in the design and conduct of the study; collection, management, analysis or interpretation of the data; review or approval of the manuscript; or decision to submit the manuscript for publication.

Author information

Authors and Affiliations

  1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA

    William B. Feldman, Doni Bloomfield, Reed F. Beall & Aaron S. Kesselheim

  2. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA

    William B. Feldman

  3. Harvard Medical School, Boston, MA, USA

    William B. Feldman, Doni Bloomfield & Aaron S. Kesselheim

  4. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

    Reed F. Beall

Authors
  1. William B. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Doni Bloomfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reed F. Beall
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aaron S. Kesselheim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William B. Feldman.

Ethics declarations

Competing interests

Outside the scope of the work, W.B.F. serves as a consultant for Alosa Health and as an expert witness in litigation against inhaler manufacturers. W.B.F. also served as a consultant to Aetion and received an honorarium for a presentation to Blue Cross Blue Shield of Massachusetts. D.B. currently serves as a judicial clerk at the US Court of Appeals for the District of Columbia Circuit. This Comment was drafted before his clerkship and represents only his personal views.

Supplementary information

Supplementary Information

Supplementary Tables 1–4

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feldman, W.B., Bloomfield, D., Beall, R.F. et al. Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD. Nat Biotechnol 40, 1319–1325 (2022). https://doi.org/10.1038/s41587-022-01451-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-022-01451-7

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research